GSK, a leading multinational pharmaceutical and biotechnology company, consistently seeks innovative solutions to develop new vaccines and specialty medicines efficiently and with top quality. In pursuit of this goal, they sought a solution to address pH variability in bioreactors, aiming to mitigate risks to product batches and reduce process drift and equipment failures.

Learn how AspenTech University can help organizations to navigate challenges and compete at the highest level with our end-to-end competency development curriculum. AspenTech University offers flexible, expert-led classes that teach the in-depth knowledge and skills required to fully apply AspenTech solutions. Learn by solving real-world problems through hands-on exercises.

Unexpected disturbances and shutdowns can severely impact any manufacturing facility. The AspenTech APM 4.0 portfolio uses agents that can be replicated quickly and easily across all plant assets to assure production and avoid unnecessary maintenance. Learn how APM 4.0 delivers an all-inclusive approach to efficiency, productivity and safety to support operational excellence in plant operations and the bottom line for manufacturers.

When Ferring Pharmaceuticals wanted to move from batch to continuous manufacturing, they found that laboratory assays were too time consuming to provide meaningful feedback for real-time control, and 100% product quality inspection was not possible.

GSK wanted to review the structure of its batch production record and associated workflows as part of a continuous improvement process.

Ferring Pharmaceuticals, a multinational biopharmaceutical company, needed a solution that would enable faster commercialization, more cost-efficient production and reduced supply lead time while maintaining product quality in support of digitalization initiatives. The company used AspenTech’s Advanced Process Analytical Technology (PAT) solution—which includes Aspen Unscrambler™ and Aspen Process Pulse™—to address this challenge.

A 140-year-old global pharmaceutical company with headquarters in Japan adopted Aspen Plus to improve the synthesis of a new active pharmaceutical ingredient (API). Aspen Plus provided an in-depth understanding of a new API process leading to equipment improvements and optimized recipes that enabled development of a continuous process.

The pandemic heightened the need for agility and resiliency within the supply chain. Speed to market remains a top business imperative as we move into the next normal for pharma.

There is great opportunity to leverage digital technologies that improve product quality and yield, process efficiency, on-time delivery and sustainability in pharma manufacturing.

We are excited to announce that the AspenTech PAT portfolio has been honored with a Pharma Manufacturing 2021 Pharma Innovation Award celebrating technologies that make advances in risk reduction. Read today’s blog to learn more.